Seladelpar NDA Submitted to FDA for Primary Biliary Cholangitis

The New Drug Application submission is supported by data from a pair of phase 3 studies, a long-term open-label study, and prior phase 2 studies. Cymabay has also requested Priority Review of the NDA.

Related Keywords

,Klara Dickinson ,Drug Administration ,Cymabay Therapeutics ,New Drug Application ,Priority Review ,Breakthrough Therapy Designation ,Cymabay Submits New Drug Application ,Primary Biliary ,Primary Biliary Cholangitis Including Pruritus ,Patients Without Cirrhosis ,With Compensated ,Improves Markers ,Cymabay Therapeutics Announces Publication ,Results From ,Primary Biliary Cholangitis ,Honda ,Fda ,Food And Drug Administration ,Seladelpar ,Cpbc ,Pruritis ,